Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis
Restricted accessResearch articleFirst published online July, 2021
Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis
To test the hypothesis that genetic predisposition to systemic lupus erythematosus (SLE) increases the risk of cardiometabolic disorders.
Methods
Using 41 single nucleotide polymorphisms (SNPs) associated with SLE, we calculated a weighted genetic risk score (wGRS) for SLE. In a large biobank we tested the association between this wGRS and 9 cardiometabolic phenotypes previously associated with SLE: atrial fibrillation, ischemic stroke, coronary artery disease, type 1 and type 2 diabetes, obesity, chronic kidney disease, hypertension, and hypercholesterolemia. Additionally, we performed a phenome-wide association analysis (pheWAS) to discover novel clinical associations with a genetic predisposition to SLE. Findings were replicated in the Electronic Medical Records and Genomics (eMERGE) Network. To further define the association between SLE-related risk alleles and the selected cardiometabolic phenotypes, we performed an inverse variance weighted regression (IVWR) meta-analysis.
Results
The wGRS for SLE was calculated in 74,759 individuals of European ancestry. Among the pre-selected phenotypes, the wGRS was significantly associated with type 1 diabetes (OR [95%CI] =1.11 [1.06, 1.17], P-value = 1.05x10−5). In the PheWAS, the wGRS was associated with several autoimmune phenotypes, kidney disorders, and skin neoplasm; but only the associations with autoimmune phenotypes were replicated. In the IVWR meta-analysis, SLE-related risk alleles were nominally associated with type 1 diabetes (P = 0.048) but the associations were heterogeneous and did not meet the adjusted significance threshold.
Conclusion
A weighted GRS for SLE was associated with an increased risk of several autoimmune-related phenotypes including type I diabetes but not with cardiometabolic disorders.
BenthamJMorrisDLGrahamDSC, et al.
Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet2015;
47: 1457–1464.
2.
AsanumaYOeserAShintaniAK, et al.
Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med2003;
349: 2407–2415.
3.
ChenSKBarbhaiyaMSolomonDH, et al.
Atrial fibrillation/flutter hospitalizations among U.S. Medicaid recipients with and without systemic lupus erythematosus. J Rheumatol2020;
47: 1359–1365.
4.
ChungCPOeserASolusJF, et al.
Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis2008;
196: 756–763.
5.
BruceINUrowitzMBGladmanDDIbanezDSteinerG.Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum2003;
48: 3159–3167.
6.
GandelmanJSKhanOAShueyMM, et al. Increased incidence of resistant hypertension in patients with systemic lupus erythematosus: a retrospective cohort study.
Hoboken:
Arthritis Care Research, 2019.
7.
MageauATimsitJFPerrozzielloA, et al.
The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev2019;
18: 733–737.
8.
KawaiVKShiMFengQ, et al.
Pleiotropy in the genetic predisposition to rheumatoid arthritis – a phenome-wide association study and inverse-variance weighted Meta-analysis. Arthritis Rheumatol2020;
72: 1483–1492.
9.
RodenDMPulleyJMBasfordMA, et al.
Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther2008;
84: 362–369.
10.
McCartyCAChisholmRLChuteCG, et al.
The eMERGE network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics2011;
4: 13.
11.
MosleyJDShoemakerMBWellsQS, et al.
Investigating the genetic architecture of the PR interval using clinical phenotypes. Circ Cardiovasc Genet2017;
10: e001482.
12.
HeldCWhiteHDStewartRAH, et al.
Inflammatory biomarkers interleukin-6 and C-Reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy)Trial. J Am Heart Assoc2017;
6.
13.
ZuvichRLArmstrongLLBielinskiSJ, et al.
Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet Epidemiol2011;
35: 887–898.
14.
ChangCCChowCCTellierLCVattikutiSPurcellSMLeeJJ.Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience2015;
4: 7.
15.
DelaneauOZaguryJFMarchiniJ.Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods2013;
10: 5–6.
16.
HowieBFuchsbergerCStephensMMarchiniJAbecasisGR.Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet2012;
44: 955–959.
17.
ZhengXLevineDShenJGogartenSMLaurieCWeirBS.A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics2012;
28: 3326–3328.
18.
WuPGiffordAMengX, et al.
Mapping ICD-10 and ICD-10-CM codes to phecodes: workflow development and initial evaluation. JMIR Med Inform2019;
7: e14325.
19.
PelletierEMOgaleSYuEBrunettaPGargJ.Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther2009;
31: 2653–2664.
20.
CarrollRJBastaracheLDennyJC.R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics2014;
30: 2375–2376.
21.
BurgessSBowdenJFallTIngelssonEThompsonSG.Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology2017;
28: 30–42.
22.
BarturenGBerettaLCerveraRVan VollenhovenRAlarcon-RiquelmeME.Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat Rev Rheumatol2018;
14: 75–93.
23.
CotsapasCVoightBFRossinE, et al.
Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet2011;
7: e1002254.
24.
RamosPSCriswellLAMoserKL, et al.
A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. PLoS Genet2011;
7: e1002406.
25.
MohlerPJSchottJJGramoliniAO, et al.
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature2003;
421: 634–639.
26.
KroupisCTheodorouMChaidaroglouA, et al.
The association between a common FCGR2A polymorphism and C-reactive protein and coronary artery disease revisited. Genet Test Mol Biomarkers2010;
14: 839–846.
27.
RiaMLagercrantzJSamnegardABoquistSHamstenAErikssonP.A common polymorphism in the promoter region of the TNFSF4 gene is associated with lower allele-specific expression and risk of myocardial infarction. PLoS One2011;
6: e17652.
28.
HeiskanenMKahonenMHurmeM, et al.
Polymorphism in the IL10 promoter region and early markers of atherosclerosis: the cardiovascular risk in Young Finns study. Atherosclerosis2010;
208: 190–196.
29.
CartyCLKeeneKLChengYC, et al.
Meta-analysis of genome-wide association studies identifies genetic risk factors for stroke in African Americans. Stroke2015;
46: 2063–2068.
30.
GudbjartssonDFBjornsdottirUSHalapiE, et al.
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet2009;
41: 342–347.
31.
MashimoYSuzukiYHatoriK, et al.
Association of TNFRSF4 gene polymorphisms with essential hypertension. J Hypertens2008;
26: 902–913.
32.
LiHHanXHuZ, et al.
Associations of NADPH oxidase-related genes with blood pressure changes and incident hypertension: the GenSalt study. J Hum Hypertens2018;
32: 287–293.
33.
LevyDEhretGBRiceK, et al.
Genome-wide association study of blood pressure and hypertension. Nat Genet2009;
41: 677–687.
34.
ScarpelliDCardelliniMAndreozziFLarattaE, et al.
Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in Caucasian Italian subjects. Diabetes2006;
55: 1529–1533.
35.
ZhouTHuZYangSSunLYuZWangG.Role of adaptive and innate immunity in type 2 diabetes mellitus. J Diabetes Res2018;
2018: 7457269.
36.
NagafuchiSKamada-HibioYHirakawaK, et al.
TYK2 promoter variant and diabetes mellitus in the Japanese. EBioMedicine2015;
2: 744–749.
37.
NejentsevSWalkerNRichesDEgholmMToddJA.Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science2009;
324: 387–389.
38.
HeinigMPetrettoEWallaceC, et al.
A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature2010;
467: 460–464.
39.
ToddJAWalkerNMCooperJD, et al.
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet2007;
39: 857–864.
40.
SwaffordADHowsonJMDavisonLJ, et al.
An allele of IKZF1 (Ikaros) conferring susceptibility to childhood acute lymphoblastic leukemia protects against type 1 diabetes. Diabetes2011;
60: 1041–1044.
41.
FungEYSmythDJHowsonJM, et al.
Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAI. P3 As a susceptibility locus. Genes Immun2009;
10: 188–191.
42.
Fernandez-RhodesLYoungKLLillyAG, et al.
Importance of genetic studies of cardiometabolic disease in diverse populations. Circ Res2020;
126: 1816–1840.
43.
SvenungssonEGustafssonJLeonardD, et al.
A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis2010;
69: 834–840.
44.
IwamotoTNiewoldTB.Genetics of human lupus nephritis. Clin Immunol2017;
185: 32–39.
45.
LeonardDSvenungssonEDahlqvistJ, et al.
Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis2018;
77: 1063–1069.
46.
PerrottiPPAteridoAFernandez-NebroA, et al.
Genetic variation associated with cardiovascular risk in autoimmune diseases. PLoS One2017;
12: e0185889.
47.
ChenLWangYFLiuL, et al.
Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity. Hum Mol Genet2020;
29: 1745–1756.
48.
ReidSAlexssonAFrodlundM, et al.
High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Ann Rheum Dis2020;
79: 363–369.
49.
ErlichHAValdesAMJulierCMirelDNobleJA; Type IDGC.
Evidence for association of the TCF7 locus with type I diabetes. Genes Immun2009;
10: S54–S59.
50.
ZouidiFStayoussefMBouzidD, et al.
Association of BANK1 and cytokine gene polymorphisms with type 1 diabetes in Tunisia. Gene2014;
536: 296–301.
51.
WinklerCLauberCAdlerK, et al.
An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes2011;
60: 685–690.
52.
AlizadehBZValdigemGCoenenMJ, et al.
Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum Mol Genet2007;
16: 2552–2559.
53.
CooperJDSmythDJWalkerNM, et al.
Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes2011;
60: 1624–1631.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
